G2GBIO Surges to Daily Limit on Obesity Treatment Hype…Genolution·Cellbion Climb[K-bio Pulse]

[Shin-Min Joon, Edaily Reporter] On August 25 South Korea’s biopharma stock market saw notable gains in G2GBIO, Genolution and Cellbion. G2GBIO surged as its long acting injectable technology drew attention, backed by the global success of obesity treatments such as Wegovy and Mounjaro. The company has also benefited from being selected for a national project to develop immunosuppressants for organ transplant patients.

Genolution advanced after announcing the development of RNA interference technology to suppress Nosema disease a fatal pathogen for honeybees. Meanwhile Cellbion climbed ahead of its upcoming Phase 2 results for a prostate cancer radioligand therapy with investor expectations building for positive outcomes.

G2GBIO stock trend on Aug 25. (Image=MP Doctor)

G2GBIO Rallies on Long Acting Injectable Pipeline

According to KG Zeroin’s MP Doctor G2GBIO shares closed at 138,500 won up 29.92% from the previous day. The company which went public on KOSDAQ on August 14 owns a proprietary drug delivery platform called InnoLAMP.

InnoLAMP extends the efficacy of treatments such as obesity, diabetes, and dementia therapies through long-acting injectable formulations. G2GBIO has also secured large-scale manufacturing processes for these drugs.

With growing global interest in obesity therapies and recent launches of Wegovy and Mounjaro in Korea market demand is rising. G2GBIO is collaborating with Boehringer Ingelheim on long acting injectables and in 2023 signed agreements with a global pharmaceutical company for diabetes obesity drug development as well as a master service agreement with a U.S. firm for microsphere based sustained release formulations.

The company has recently completed successful Phase 1 trials in Canada and Korea for its one month Alzheimer’s treatment candidates GB-5001 and GB-5001A. It also wrapped up a Phase 1 trial of its postoperative pain treatment GB-6002 which provides over three days of sustained efficacy. Pipeline development continues with GB-7001 a one month diabetes and obesity therapy.

Adding to its momentum G2GBIO was recently selected by Korea’s Ministry of Trade, Industry and Energy for a 2.5year, 2.5 billion won R&D project focused on developing a one month immunosuppressant for organ transplant patients using InnoLAMP.

An industry official commented “G2GBIO’s corporate value is rising alongside the global spotlight on obesity treatments. The company is accelerating its competitiveness in CNS and metabolic diseases.”

Genolution Develops RNAi Technology Against Nosema Disease in Honeybees

Genolution shares rose 10.92% to close at 2,590 won. Buying interest was fueled by news that the company published results in an international journal on RNA interference (RNAi) technology suppressing Nosema, a fatal honeybee pathogen. The research appeared in Chemical and Biological Technologies in Agriculture (CBTA) a Q1 ranked journal with an impact factor of 5.2.

The study demonstrated suppression of Nosema infection using designed double stranded RNA (dsRNA) and crucially provided the world’s first fluorescent imaging evidence of the pathogen directly absorbing and responding to dsRNA. This breakthrough shows RNAi technology can act directly on pathogens without relying on the host mechanism, boosting its potential as a next-generation pest control strategy.

A Genolution spokesperson said “This publication validates the academic and industrial value of our dsRNA platform. We are accelerating R&D to enter clinical trials within three years and plan to expand eco-friendly pest control solutions for honeybees and broader agriculture.”

Cellbion Advances Ahead of Phase 2 Prostate Cancer Therapy Results

Cellbion rose 7.58% to close at 28,400 won, driven by expectations for topline Phase 2 results of its prostate cancer radioligand therapy (RLT), Lu-177-DGUL. The results are expected by late August or early September. Based on the data, Cellbion plans to file for product approval with Korea’s Ministry of Food and Drug Safety (MFDS) this year aiming for commercialization in 2026.

Lu-177-DGUL has been selected as a clinical stage project by the Korea Drug Development Fund (KDDF) and was designated as a developmental rare drug by MFDS in 2021 and a Global Innovative Product on the Fast Track (GIFT) in 2023. This opens the door for conditional approval following Phase 2. Industry forecasts suggest annual domestic sales could reach 20 billion won upon launch.

Currently the prostate cancer RLT market is dominated by Novartis’ Pluvicto which posted $825 million in first half 2025 global sales up 32% year over year. While global competitors are still in clinical stages, Cellbion’s Lu-177-DGUL could challenge Pluvicto’s monopoly once commercialized.

A Cellbion representative stated “We are doing our utmost to keep Lu-177-DGUL’s development timeline on track.”